InsiderTrades

Form 4 for SPRY ARS Pharmaceuticals, Inc.

Accepted 2022-11-10 00:00:00 ET · period of report 2022-11-08 · accession 0001209191-22-056443 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2022-11-10 2022-11-08 SPRY Tanimoto Sarina Chief Medical Off, 10% A - Grant — +7.87M 1.77M New —
D 2022-11-10 2022-11-08 SPRY Tanimoto Sarina Chief Medical Off, 10% A - Grant — +4.33M 4.33M New —
DM 2022-11-10 2022-11-08 SPRY Tanimoto Sarina Chief Medical Off, 10% A - Grant — +165.5K 82.7K New —
DMI 2022-11-10 2022-11-08 SPRY Tanimoto Sarina Chief Medical Off, 10% A - Grant — +472.8K 236.4K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2022-11-08 A A 1,772,850 — 1,772,850 I By Richard Lowenthal Charitable Remainder Unitrust Dated January 7, 2020 — — (F2) Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement. (F4) The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
2 Common Common Stock 2022-11-08 A A 4,326,854 — 4,326,854 D By Sarina Tanimoto Charitable Remainder Unitrust Dated January 7, 2020 — — (F1) Received in exchange for 3,660,930 shares of common stock of ARS Pharmaceuticals, Inc. ("ARS") pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), as amended (the "Merger Agreement"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the "Merger"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of ARS common stock was converted into the right to receive 1.1819 shares of the Issuer common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc. (F3) The Reporting Person is trustee of the trust.
3 Common Common Stock 2022-11-08 A A 4,326,854 — 4,326,854 I — — (F5) Received in exchange for 3,660,930 shares of common stock of ARS pursuant to the Merger Agreement.
4 Common Common Stock 2022-11-08 A A 1,772,850 — 1,772,850 I By spouse — — (F2) Received in exchange for 1,500,000 shares of common stock of ARS pursuant to the Merger Agreement.
5 Derivative Employee Stock Option (Right to Buy) 2022-11-08 A A 82,733 — 82,733 D By spouse $0.84 · — to 2029-12-16 82,733 Common Stock (F7) Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $0.99 per share pursuant to the Merger Agreement. (F8) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F6) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
6 Derivative Employee Stock Option (right to buy) 2022-11-08 A A 82,733 — 82,733 D By spouse $1.44 · — to 2031-12-13 82,733 Common Stock (F9) Received in exchange for a stock option to acquire 70,000 shares of common stock of ARS with the exercise price of $1.70 per share pursuant to the Merger Agreement. (F8) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F6) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
7 Derivative Employee Stock Option (right to buy) 2022-11-08 A A 236,380 — 236,380 I $0.84 · — to 2029-12-16 236,380 Common Stock (F10) Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $0.99 per share pursuant to the Merger Agreement. (F8) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F6) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.
8 Derivative Employee Stock Option (right to buy) 2022-11-08 A A 236,380 — 236,380 I $1.44 · — to 2031-12-13 236,380 Common Stock (F8) Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. (F11) Received in exchange for a stock option to acquire 200,000 shares of common stock of ARS with an exercise price of $1.70 per share pursuant to the Merger Agreement. (F6) 25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date.